Laure-Anne Van Bellinghen

The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model

Laure-Anne Van Bellinghen, Genevieve Meier, Ilse Van Vlaenderen · PLoS ONE · 2014 · 67 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacoeconomics +17

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model

F Christiaan K Dolk, Martin Eichner, R Welte et al. · PharmacoEconomics · 2016 · 41 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacoeconomics +17

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

Daniel Molnar, Elizabeth M. La, Frederik Verelst et al. · Infectious Diseases and Therapy · 2024 · 26 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries

Christophe Sauboin, Laure-Anne Van Bellinghen, Nicolas Van de Velde et al. · MDM Policy & Practice · 2019 · 20 citations · Full text

Veterinary Medicine, Child Health, Infectious Diseases +17

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types

Laure-Anne Van Bellinghen, Alen Marijam, Gabriela Tannus Branco de Araújo et al. · The Brazilian Journal of Infectious Diseases · 2018 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacoeconomics +17